PL2720701T3 - Terapeutyczne pozajelitowe zastosowanie oleju z kryla - Google Patents

Terapeutyczne pozajelitowe zastosowanie oleju z kryla

Info

Publication number
PL2720701T3
PL2720701T3 PL12731667T PL12731667T PL2720701T3 PL 2720701 T3 PL2720701 T3 PL 2720701T3 PL 12731667 T PL12731667 T PL 12731667T PL 12731667 T PL12731667 T PL 12731667T PL 2720701 T3 PL2720701 T3 PL 2720701T3
Authority
PL
Poland
Prior art keywords
gelling
application
krill oil
therapeutic non
therapeutic
Prior art date
Application number
PL12731667T
Other languages
English (en)
Polish (pl)
Inventor
David F Driscoll
Original Assignee
Stable Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/161,101 external-priority patent/US8895074B2/en
Application filed by Stable Solutions Llc filed Critical Stable Solutions Llc
Publication of PL2720701T3 publication Critical patent/PL2720701T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/612Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12731667T 2011-06-15 2012-06-13 Terapeutyczne pozajelitowe zastosowanie oleju z kryla PL2720701T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/161,101 US8895074B2 (en) 2011-06-15 2011-06-15 Therapeutic application of parenteral krill oil
EP11179821 2011-09-02
PCT/IB2012/001156 WO2012172411A1 (en) 2011-06-15 2012-06-13 Therapeutic application of parenteral krill oil
EP12731667.7A EP2720701B1 (en) 2011-06-15 2012-06-13 Therapeutic application of parenteral krill oil

Publications (1)

Publication Number Publication Date
PL2720701T3 true PL2720701T3 (pl) 2018-01-31

Family

ID=46456944

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12731667T PL2720701T3 (pl) 2011-06-15 2012-06-13 Terapeutyczne pozajelitowe zastosowanie oleju z kryla

Country Status (22)

Country Link
EP (1) EP2720701B1 (enExample)
JP (1) JP5864735B2 (enExample)
KR (1) KR101841588B1 (enExample)
CN (2) CN107648268B (enExample)
BR (1) BR112013032224B1 (enExample)
CA (1) CA2838312C (enExample)
CY (1) CY1119417T1 (enExample)
DK (1) DK2720701T3 (enExample)
ES (1) ES2643843T3 (enExample)
HR (1) HRP20171431T1 (enExample)
HU (1) HUE036720T2 (enExample)
IL (1) IL229690A (enExample)
LT (1) LT2720701T (enExample)
MX (1) MX351895B (enExample)
PL (1) PL2720701T3 (enExample)
PT (1) PT2720701T (enExample)
RS (1) RS56394B1 (enExample)
RU (1) RU2625760C2 (enExample)
SI (1) SI2720701T1 (enExample)
SM (1) SMT201700470T1 (enExample)
TW (1) TWI592160B (enExample)
WO (1) WO2012172411A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993980B1 (en) 2013-05-10 2023-11-01 Memorial Sloan Kettering Cancer Center Lipid scavenging in ras cancers
GB201402457D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Capsules containing high doses of phospholipids
GB201402450D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
GB201407345D0 (en) 2014-04-25 2014-06-11 Aker Biomarine As Krill Phospholipid compositions
PL3137070T3 (pl) * 2014-04-30 2020-07-13 Aker Biomarine Antarctic As Preparaty z oleju z kryla i ich zastosowania
EP3232798A1 (en) 2014-12-19 2017-10-25 Aker Biomarine Antarctic AS Enhanced omega-3 formulations
JP6814148B2 (ja) * 2015-03-31 2021-01-13 フレゼニウス カービ ドイチュラント ゲーエムベーハー 非経口投与用のエマルション
CN105901740A (zh) * 2016-04-26 2016-08-31 济南极源生物科技有限公司 一种南极磷虾油可食用营养品
CN118000419A (zh) * 2017-08-10 2024-05-10 儿童医疗中心有限公司 与包含鱼油和/或ω-3脂肪酸的乳剂有关的方法和组合物
EP3536332A1 (en) * 2018-03-07 2019-09-11 Athenion AG Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
KR102451162B1 (ko) * 2020-09-07 2022-10-06 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
JPH08231391A (ja) * 1995-02-24 1996-09-10 Kanagawa Kagaku Kenkyusho:Kk 痴呆症状改善薬
ATE497384T1 (de) * 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
DK1997498T3 (da) * 2001-06-18 2012-07-30 Neptune Technologies & Bioressources Inc Krillekstrakter til forebyggelse og/eller behandling af kardiovaskulære sygdomme
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
CN101321477A (zh) * 2005-10-07 2008-12-10 加拿大海洋营养食品有限公司 脂肪酸盐及其制备和使用方法
CL2007003283A1 (es) * 2006-11-16 2008-05-23 Pronova Biopharma Norge As Proceso para extraer una fraccion casi total de lipidos a partir del krill fresco que comprende reducir el contenido de agua de la materia prima y aislar la fraccion de lipidos; fraccion casi total de lipidos; proceso para separar fosfolipidos; fracc
WO2008117062A1 (en) 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions
JP5443979B2 (ja) * 2007-05-11 2014-03-19 備前化成株式会社 新規のロイコトリエン受容体アンタゴニスト
NO327925B1 (no) * 2007-06-25 2009-10-19 Pharmalogica As Anvendelse av kullsyre i drikker omfattende polyumettede fettsyrer (PUFA) for a hindre oksidasjon av fettsyrene.
US20090099261A1 (en) * 2007-09-25 2009-04-16 Isi Brands Inc. Omega-3 mixtures
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US20100130619A1 (en) * 2008-11-24 2010-05-27 Joseph Schwarz Pharmaceutical composition for parenteral administration of idebenone
US8241672B2 (en) 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
NO333013B1 (no) * 2009-07-06 2013-02-18 Smartfish As Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
US8609157B2 (en) * 2009-10-30 2013-12-17 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils

Also Published As

Publication number Publication date
TWI592160B (zh) 2017-07-21
BR112013032224A2 (pt) 2016-12-20
EP2720701B1 (en) 2017-08-09
CA2838312A1 (en) 2012-12-20
KR20140053957A (ko) 2014-05-08
JP5864735B2 (ja) 2016-02-17
SI2720701T1 (sl) 2017-12-29
RU2014101067A (ru) 2015-07-20
LT2720701T (lt) 2017-11-10
MX2013014901A (es) 2014-07-09
WO2012172411A1 (en) 2012-12-20
CN107648268A (zh) 2018-02-02
JP2014517028A (ja) 2014-07-17
RU2625760C2 (ru) 2017-07-18
TW201302209A (zh) 2013-01-16
BR112013032224B1 (pt) 2021-10-13
SMT201700470T1 (it) 2018-01-11
CN107648268B (zh) 2021-06-22
PT2720701T (pt) 2017-10-23
EP2720701A1 (en) 2014-04-23
CA2838312C (en) 2019-01-08
IL229690A0 (en) 2014-01-30
HUE036720T2 (hu) 2018-07-30
IL229690A (en) 2017-01-31
CY1119417T1 (el) 2018-03-07
KR101841588B1 (ko) 2018-03-26
DK2720701T3 (en) 2017-10-30
ES2643843T3 (es) 2017-11-24
MX351895B (es) 2017-11-01
CN103608023A (zh) 2014-02-26
HRP20171431T1 (hr) 2017-12-15
RS56394B1 (sr) 2017-12-29

Similar Documents

Publication Publication Date Title
PL2720701T3 (pl) Terapeutyczne pozajelitowe zastosowanie oleju z kryla
SMT201700094B (it) Composto di pirazina carbossammide
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
EP2713762A4 (en) Stevia-COMPOSITION
PL2895144T3 (pl) Kompozycje semifluorowanych alkanów
EP2736491A4 (en) BEPOTASTIN COMPOSITION
CO7061086A2 (es) Combinaciones de compuestos activos
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
IL227764A0 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
EP2709972A4 (en) NON-FLAMMABLE COMPOSITIONS FROM CHLORINE TRIFLUORPROPES
CO7010824A2 (es) Inhibidores de aplicación viral
SMT201600410B (it) Modulatori diidropirazolici di gpr40
AR092198A1 (es) Derivados de pirazolopirimidinas
PL2772482T3 (pl) Pochodna azolu
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
CO6791617A2 (es) Combinaciones de compuestos activos
EP2881113A4 (en) NEW USE OF POGOSTON
SI3246325T1 (sl) Kristali 2-acilaminotiazol spojine
EP2858975A4 (en) FBXO3 INHIBITORS
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
EP2914249A4 (en) TRANSDERMAL PROPYNYLAMINOINDANE COMPOSITIONS
EP2762310A4 (en) POWER BODY
CR20130603A (es) Compuestos novedosos como inhibidores de diacilglicerol